Optain

What Optain does

Optain Health is a private AI medical device and software company that builds non-invasive, AI-enabled clinical support tools which analyse full-colour retinal images to screen for eye diseases and, through its Assure+ product, assess cardiovascular disease risk. The company's core technology stack consists of the AI-based oculomics platform (developed by Professor Mingguang He and collaborators at the University of Melbourne, Centre for Eye Research Australia, and Monash eResearch Centre), the Eyetelligence Assure and Assure+ Software-as-a-Medical-Device products trained on over 1,000,000 retinal images, and the FDA 510(k)-cleared Resolve Camera — a robotic, portable, automatic fundus camera with voice command and cloud connectivity. Machine learning algorithms analyse retinal photographs and microvasculature to detect diabetic retinopathy, glaucoma, age-related macular degeneration, and cardiovascular risk with reported accuracy above 90%.

Optain monetizes through a combination of recurring AI SaMD subscriptions/licensing, hardware sales of the Resolve Camera (available internationally but not as a standalone in the U.S.), and professional teleophthalmology grading services delivered via the EyePACS network acquired in November 2025. The company sells direct to U.S. health systems, primary care providers, health plans, and FQHCs, and operates channel partnerships with Australian optometry chains Bupa Optical and George & Matilda, plus a Malaysia partnership with Garli Medi Tech for medical tourism distribution. Pricing is quote-based and not publicly disclosed, and Assure+ is currently not available for sale in the U.S. market.

The company was launched in May 2023 by Northwell Health and Aegis Ventures through the Ascertain platform with a $12M seed round, building on technology developed by the predecessor Australian company Eyetelligence (founded 2019). Optain is headquartered in New York with R&D and legal manufacturing in Melbourne via wholly-owned subsidiary Eyetelligence Pty Ltd, qualified across more than 30 countries, and has raised a total of $38M across two rounds, including a $26M Series A led by Insight Partners in September 2025 with participation from seven major U.S. health systems.

Name

Optain

Legal name

Optain Health

Website

https://optainhealth.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Optain Health is a private AI medical device company whose Eyetelligence Assure software and FDA-cleared Resolve Camera analyse retinal images to screen for diabetic retinopathy, glaucoma, AMD, and cardiovascular risk for health systems, primary care providers, payers, and optometry chains.

Ownership category

akta.pro rank

Product category

AI-Enabled Retinal Imaging and Diagnostics

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industry

Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)

Keywords

• AI retinal imaging
• Oculomics diagnostics
• Diabetic retinopathy screening
• Cardiovascular risk assessment
• Teleophthalmology software

Headquarters

HQ city

Akron

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Others

Revenue model

1. AI Software as a Medical Device (SaMD): Subscription or licensing model for Eyetelligence Assure and Assure+ software products. Software analyzes retinal images for disease detection and cardiovascular risk assessment.
2. Hardware Sales - Resolve Camera: Sale of FDA-cleared robotic fundus cameras to healthcare providers. Camera not available for sale in US as standalone product; available internationally.
3. Teleophthalmology Grading Services: Rapid teleophthalmology grading services where licensed Optain graders return ICD-10-coded reports, typically same day.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

Optain sells AI-enabled Software as a Medical Device (Eyetelligence Assure and Assure+) that analyzes retinal fundus images to screen for diabetic retinopathy, glaucoma, age-related macular degeneration, and cardiovascular disease risk, bundled with an FDA 510(k)-cleared portable robotic Resolve Camera as a turnkey point-of-care screening solution for clinicians. The company also operates teleophthalmology grading services that return ICD-10-coded reports to providers via integrated EHR workflows.

Product overview

Optain offers a unified product portfolio combining AI-enabled Software as a Medical Device (SaMD) with hardware for AI-driven retinal imaging and early disease detection. The core offering consists of Eyetelligence Assure and Eyetelligence Assure+ software products that analyze retinal images to screen for eye diseases and cardiovascular risk, paired with the Resolve Camera—a portable automated fundus camera. The company also acquired EyePACS, a teleophthalmology network, to expand access. All products are powered by an AI-based oculomics platform that leverages machine learning algorithms trained on over 1,000,000 retinal images.

Differentiator

Problem solved

Functional benefit

Brands

• Eyetelligence Assure: AI-enabled Software as a Medical Device (SaMD) for eye disease screening and cardiovascular risk assessment
• Resolve Camera

Products and services

• Eyetelligence Assure AI-enabled Software as a Medical Device (SaMD) that analyzes digital retinal images to detect eye diseases including diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD) with accuracy exceeding 90%. Trained on over 1,000,000 retinal images. Designed for healthcare providers, primary care, optometry, and health systems.
• Eyetelligence Assure+ Enhanced AI-enabled SaMD that detects eye diseases plus screens for cardiovascular disease risk by analyzing retinal microvasculature, achieving overall accuracy exceeding 90% for both eye diseases and cardiovascular risk assessment. Cardiovascular risk detection with over 85% accuracy via heatmap-based microvasculature analysis.
• Resolve Camera Portable Automatic Fundus Camera with automated eye detection, focus, and adjustment features. FDA 510(k)-cleared Class 1 Medical Device with voice command functionality, cloud connectivity, 16G internal memory, and up to 4 hours battery life. Designed for point-of-care retinal imaging in primary care without dilation. Not available for sale in the US as a standalone product.
• EyePACS Teleophthalmology Network Nationwide teleophthalmology network acquired by Optain Health to enhance retinal imaging access across the U.S. and globally, enabling AI-driven early disease detection with integrated workflow solutions.
• Teleophthalmology Grading Services Professional teleophthalmology grading service where licensed Optain graders return ICD-10-coded reports, typically same day, integrating directly into provider EHR workflows.

Quantifiable outcome

• Up to 95% accuracy for detecting eye diseases (glaucoma, AMD, diabetic retinopathy)
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor, core and major.

• Garli Medi TechminorStrategic or Co-development Partner · 1 January 2026Partnership in Malaysia integrating AI and telehealth solutions for medical tourism market expansion.
• EyePACScoreStrategic or Co-development Partner · 1 November 2025Acquired nationwide teleophthalmology network to enhance retinal imaging access across the U.S. and globally. Expands early disease detection capabilities with advanced AI and integrated workflow solutions.
• Monash eResearch CentrecoreTechnology or Integration · 1 January 2020Technology and algorithm development partnership for AI eye screening system development. Part of MRFF-funded research project led by Professor Mingguang He.
• Centre for Eye Research AustraliacoreStrategic or Co-development PartnerResearch partnership with Professor Mingguang He for AI oculomics technology development. Research published in top academic journals.
• University of MelbournecoreStrategic or Co-development PartnerAcademic research partnership with Professor Mingguang He for AI ophthalmology technology development. Professor He is Professor of Ophthalmic Epidemiology at the university.
• Bupa OpticalmajorChannel Partner/ Reseller/ DistributorMajor optometry chain in Australia using Eyetelligence/Optain AI retinal screening products in their stores.
• George & MatildamajorChannel Partner/ Reseller/ DistributorAustralian optometry chain using Eyetelligence/Optain AI retinal screening products in their stores.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• AEYE Health: AEYE Health develops FDA-cleared AI for autonomous retinal screening (AEYE-DS) for diabetic retinopathy. Operates in the same point-of-care screening workflow as Optain, often paired with portable fundus cameras.
• Eyenuk: Eyenuk's EyeArt is an FDA-cleared AI system for autonomous detection of diabetic retinopathy, directly competing in the same AI retinal screening category as Eyetelligence Assure. Targets primary care and optometry channels.
• Digital Diagnostics (IDx-DR): Digital Diagnostics pioneered FDA-authorized autonomous AI diagnostic systems, most notably IDx-DR for diabetic retinopathy screening at point-of-care. Direct competitor in AI-based retinal disease detection targeting primary care.

Emerging players

• Sight Diagnostics: Sight Diagnostics applies computer vision to blood analysis (OLO) and has explored adjacent point-of-care AI diagnostics; an emerging player with comparable AI-driven diagnostic imaging approach but currently focused on hematology rather than retinal screening.
• RetinAI Medical (Ikerian): RetinAI (formerly Ikerian) is an emerging AI medical imaging company focused on ophthalmology and oculomics, providing AI for retinal image analysis and clinical workflow tools. Comparable emerging player in the same retinal AI niche with overlap in disease detection and systemic health insights.

Broad incumbents

• Heidelberg Engineering: Heidelberg Engineering manufactures premium ophthalmic imaging systems (Spectralis OCT, HRT, fundus imaging) used in ophthalmology clinics. Broad incumbent with diagnostic hardware that competes for the same clinical workflow that Optain targets.
• Verily (Alphabet): Verily (Alphabet) has invested in precision medicine and AI-driven retinal screening through collaborations and internal projects (e.g., diabetic retinopathy screening partnerships). Broad incumbent with deep R&D resources and potential to compete across multiple disease categories.
• Topcon Healthcare: Topcon is a major ophthalmic device manufacturer with fundus cameras, OCT, and a software ecosystem (Harmony, Imagenet). Broad incumbent offering competing hardware and increasingly integrated AI screening in optometry and ophthalmology practices.
• Carl Zeiss Meditec: Zeiss Meditec is a global leader in ophthalmic diagnostics (fundus imaging, OCT, perimetry) and integrated software. As a broad incumbent, it can bundle AI screening capabilities into its extensive installed base of ophthalmic imaging devices.
• Google Health (Retinal AI): Google has published seminal research on AI retinal image analysis (e.g., cardiovascular risk from retinal photos in Nature Biomedical Engineering) and has partnerships with health systems including India's Aravind Eye Hospital. Represents a broad incumbent threat with research parity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/optainhealth

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optain